Kraj: Unia Europejska
Język: angielski
Źródło: EMA (European Medicines Agency)
filgrastim
Accord Healthcare S.L.U.
L03AA02
filgrastim
Immunostimulants,
Neutropenia
Grastofil is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia.The safety and efficacy of Grastofil are similar in adults and children receiving cytotoxic chemotherapy.Grastofil is indicated for the mobilisation of peripheral blood progenitor cells (PBPCs).In patients, children or adults with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of ≤ 0.5 x 109/L, and a history of severe or recurrent infections, long term administration of Grastofil is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.Grastofil is indicated for the treatment of persistent neutropenia (ANC less than or equal to 1.0 x 109/L) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate.
Revision: 14
Authorised
2013-10-17
49 B. PACKAGE LEAFLET 50 PACKAGE LEAFLET: INFORMATION FOR THE USER GRASTOFIL 30 MU/0.5 ML SOLUTION FOR INJECTION/INFUSION IN PRE-FILLED SYRINGE filgrastim READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor, pharmacist or nurse. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Grastofil is and what it is used for 2. What you need to know before you use Grastofil 3. How to use Grastofil 4. Possible side effects 5. How to store Grastofil 6. Contents of the pack and other information 1. WHAT GRASTOFIL IS AND WHAT IT IS USED FOR Grastofil contains the active substance filgrastim. Grastofil is a white blood cell growth factor (granulocyte colony stimulating factor) and belongs to a group of medicines called cytokines. Growth factors are proteins that are produced naturally in the body but they can also be made using biotechnology for use as a medicine. Grastofil works by encouraging the bone marrow to produce more white blood cells. A reduction in the number of white blood cells (neutropenia) can occur for several reasons and makes your body less able to fight infection. Filgrastim stimulates the bone marrow to produce new white cells quickly. Grastofil can be used: to increase the number of white blood cells after treatment with chemotherapy to help prevent infections; to increase the number of white blood cells after a bone marrow transplant to help prevent infections; to increase the number of white blood cells if you suffer from severe chronic neutropenia to help prevent infections; in patients with advanced HIV infection which will Przeczytaj cały dokument
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT Grastofil 30 MU/0.5 ml solution for injection/infusion in pre-filled syringe 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each pre-filled syringe contains 30 million units (MU)/300 micrograms of filgrastim in 0.5ml (0.6 mg/ml) solution for injection/infusion. Filgrastim is a recombinant methionyl human granulocyte-colony stimulating factor produced in _Escherichia coli _ (BL21) by recombinant DNA technology. Excipient with known effect: Each ml of solution contains 50 mg of sorbitol (E420). _ _ For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection/infusion. Clear, colourless solution. 4. CLINCAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Grastofil is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia. The safety and efficacy of Grastofil are similar in adults and children receiving cytotoxic chemotherapy. Grastofil is indicated for the mobilisation of peripheral blood progenitor cells (PBPCs). In patients, children or adults with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of ≤ 0.5 x 10 9 /L, and a history of severe or recurrent infections, long term administration of Grastofil is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events. Grastofil is indicated f or the treatment of persistent neutropenia (ANC less than or equal to 1.0 x 10 9 /L) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate. Przeczytaj cały dokument